Jazz Pharmaceuticals Launches Evidence-Based Sodium Reduction Education for Sleep Disorder Patients
Jazz Pharmaceuticals has teamed up with the American Nutrition Association to develop evidence-based educational materials on sodium reduction for patients with narcolepsy and idiopathic hypersomnia, who face elevated cardiovascular and cardiometabolic risks. The initiative will equip clinicians with peer-reviewed resources and empower patients to limit total daily sodium exposure.
1. Partnership Details
Jazz Pharmaceuticals has formed a collaboration with the American Nutrition Association to create evidence-based educational programming focused on reducing sodium intake for individuals with narcolepsy and idiopathic hypersomnia, who are at increased cardiovascular and cardiometabolic risk due to elevated blood pressure sensitivity.
2. Patient and Clinician Resources
The initiative will translate current nutrition science into patient-centered guidance that outlines daily sodium limits from food, beverages and medications, and will provide clinicians with peer-to-peer tools to counsel patients on modifiable risk factors and cardiovascular risk mitigation.
3. Program Rollout and Future Plans
Programming will be rolled out in phases, with additional details on digital resources, training modules and patient outreach expected later this year, aiming to enhance treatment outcomes beyond pharmacological interventions.